Patents Assigned to Drugtech Corporation
  • Publication number: 20130189374
    Abstract: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 25, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan David Bortz, Mitchell Kirschner
  • Publication number: 20130184245
    Abstract: A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.
    Type: Application
    Filed: January 3, 2013
    Publication date: July 18, 2013
    Applicant: DRUGTECH CORPORATION
    Inventor: DRUGTECH CORPORATION
  • Publication number: 20130172279
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: July 25, 2012
    Publication date: July 4, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Publication number: 20130102548
    Abstract: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 ?g to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.
    Type: Application
    Filed: July 23, 2012
    Publication date: April 25, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Thomas C. Riley, R. Saul Levinson, Robert C. Cuca, Elio Mariani
  • Patent number: 8057433
    Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: November 15, 2011
    Assignee: DrugTech Corporation
    Inventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
  • Publication number: 20110276030
    Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
    Type: Application
    Filed: July 8, 2005
    Publication date: November 10, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
  • Publication number: 20110251141
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Publication number: 20110152840
    Abstract: The present invention relates to methods and kits for reducing the occurrence of preterm delivery and other pregnancy-related conditions in pregnant female subjects exhibiting one or more risk factors for preterm delivery and other pregnancy-related conditions. For example, the present invention relates to methods for reducing the occurrence of preterm delivery in a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery (e.g., smoking during pregnancy). The methods and kits provide for the administration of a steroid hormone to the pregnant female subject.
    Type: Application
    Filed: December 17, 2010
    Publication date: June 23, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Chang Lee, Robert Birch
  • Publication number: 20110015150
    Abstract: Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.
    Type: Application
    Filed: September 27, 2010
    Publication date: January 20, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan David Bortz, Mitchell I. Kirschner, David S. Hermelin
  • Publication number: 20100184642
    Abstract: The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins.
    Type: Application
    Filed: January 22, 2009
    Publication date: July 22, 2010
    Applicant: DrugTech Corporation
    Inventors: Lars Erik Berglund, Torben Ellebaek Petersen, Sergey Nikolaevich Fedosov, Ebba Nexo, Niels Bech Laursen, Erik Ostergaard Jensen
  • Patent number: 7727972
    Abstract: The present invention relates to a method for determining absorption of cobalamin or analogues thereof in an individual comprising (ii providing two blood samples from said individual, wherein the first sample comprises said individual's blood prior to ingestion by said individual of non-radioactive cobalamin or an analogue thereof and the second sample comprises said individual's blood after said ingestion, (ii) determining the concentration of cobalamin or analogue thereof in the first sample, (iii) determining the concentration of cobalamin or analogue thereof in the second sample by treating complexes of cobalamin or analogue thereof and one or more carrier proteins with one or more enzymes to release cobalamin or analogue thereof from said one or more carrier proteins, and (iv) determining, on the basis of comparison of said concentrations in said two samples, whether said cobalamin or analogue thereof has been absorbed in the blood stream.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: June 1, 2010
    Assignee: DrugTech Corporation
    Inventors: Ebba Nexø, Anne Louise Mørkbak
  • Publication number: 20100129496
    Abstract: This invention relates to novel nutritional supplements comprising essential fatty acids and iron, as well as methods related thereto.
    Type: Application
    Filed: October 14, 2009
    Publication date: May 27, 2010
    Applicant: DRUGTECH CORPORATION
    Inventors: Mitchell I. Kirschner, R. Saul Levinson
  • Publication number: 20090270503
    Abstract: The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provides improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.
    Type: Application
    Filed: October 29, 2008
    Publication date: October 29, 2009
    Applicant: DRUGTECH CORPORATION
    Inventors: Marc S. Hermelin, R. Saul Levinson, George Paradissis
  • Publication number: 20090098069
    Abstract: An alcohol-free, transdermal drug delivery composition administered via a metered spray drug delivery device is described herein. The non-occlusive transdermal drug delivery composition includes a therapeutically effective amount of at least one physiologically active agent or prodrug thereof, an effective amount of at least one dermal penetration enhancer; and at least one non-volatile liquid. The transdermal drug delivery composition is administered to a dermal or mucosal surface of an animal needing the same using a metered spray device capable of delivering a fine spray of substantially uniform particle size to minimize the required drying time therefor.
    Type: Application
    Filed: September 12, 2008
    Publication date: April 16, 2009
    Applicant: DRUGTECH CORPORATION
    Inventor: Rita Downard Vacca
  • Publication number: 20090075963
    Abstract: The present invention provides a transdermal spray drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention.
    Type: Application
    Filed: September 12, 2008
    Publication date: March 19, 2009
    Applicant: DRUGTECH CORPORATION
    Inventors: R. Saul Levinson, Larry G. Miller
  • Publication number: 20090068190
    Abstract: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.
    Type: Application
    Filed: August 27, 2008
    Publication date: March 12, 2009
    Applicant: DRUGTECH CORPORATION
    Inventor: Jonathan David Bortz
  • Publication number: 20090068289
    Abstract: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same.
    Type: Application
    Filed: November 14, 2008
    Publication date: March 12, 2009
    Applicant: DRUGTECH CORPORATION
    Inventors: R. Saul Levinson, Marc S. Hermelin, Mitchell I. Kirschner
  • Publication number: 20090035370
    Abstract: A method for treating a medical condition for which quetiapine is indicated in a subject comprises comprising orally administering to the subject quetiapine or a pharmaceutically acceptable salt thereof in a daily dosage amount effective to treat said condition; wherein the quetiapine or salt thereof is administered in one to a plurality of dosage forms collectively comprising (a) a major quetiapine component in immediate-release form in a sedative effective amount, administered not earlier than about 3 hours prior to the start of a sleep period; and (b) either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein time of administration and release properties of the minor component provide substantial onset of release of quetiapine therefrom not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following th
    Type: Application
    Filed: July 31, 2008
    Publication date: February 5, 2009
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan David Bortz, Michael Norman Grimshaw
  • Publication number: 20090035385
    Abstract: Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; and about 5 mg to about 500 mg of one or more forms of an organic acid. In another embodiment, the composition includes about 50 to about 150 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; about 50 to about 250 mg of one or more forms of an organic acid; about 150 to about 250 mg of one or more forms of ascorbic acid; about 0.5 mg to about 1.5 mg vitamin B12; about 50 to about 150 mg intrinsic factor; and about 0.5 mg to about 1.5 mg folic acid.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 5, 2009
    Applicant: DRUGTECH CORPORATION
    Inventor: Jonathan David Bortz
  • Publication number: 20090028962
    Abstract: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.
    Type: Application
    Filed: November 9, 2005
    Publication date: January 29, 2009
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan David Bortz, Mitchell Kirschner